Key regions: Germany, United States, India, Japan, United Kingdom
Russia, one of the largest countries in the world, has a growing demand for Anti-Rheumatic Drugs.
Customer preferences: The customer preferences in Russia for anti-rheumatic drugs are similar to those of other countries. Patients suffering from rheumatic diseases prefer drugs that are effective, have fewer side effects, and are affordable. They also prefer drugs that can be taken orally and have a long-lasting effect.
Trends in the market: The Anti-Rheumatic Drugs market in Russia is growing due to an increase in the prevalence of rheumatic diseases. The aging population is a significant factor contributing to the growth of this market. According to the United Nations, the population of Russia is expected to decline by 10% by 2050. This means that the percentage of people aged 60 and over will increase, leading to a higher prevalence of rheumatic diseases.
Local special circumstances: Russia has a unique healthcare system that is different from other countries. The healthcare system is mainly funded by the government, and patients have to pay a small fee for medical services. This means that the government plays a significant role in determining which drugs are available to patients. The government also regulates drug prices, which can affect the availability of drugs in the market.
Underlying macroeconomic factors: The Russian economy is heavily dependent on oil and gas exports, which can affect the availability of foreign currency. This can result in a shortage of imported drugs, affecting the availability of anti-rheumatic drugs in the market. The political situation in Russia can also affect the market. Sanctions imposed by other countries can affect the availability of drugs in the market and can also affect the economy. In conclusion, the Anti-Rheumatic Drugs market in Russia is growing due to an increase in the prevalence of rheumatic diseases. The customer preferences in Russia for anti-rheumatic drugs are similar to those of other countries. The unique healthcare system and the political situation in Russia can affect the availability of drugs in the market. The Russian economy's dependence on oil and gas exports can also affect the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
